Q-omics provides the consensus-scored MUC20 profile across patient tissues and cancer cell-line models. MUC20 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MUC20 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MUC20 RNA expression shows 15,814 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where MUC20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC20 survival associations across molecular data types. MUC20 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC20 RNA expression–survival associations across cancer types. High MUC20 expression shows unfavorable associations in OV, COAD and READ, but favorable associations in KIRC, HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MUC20 RNA expression.
This table summarizes MUC20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MUC20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC20 shows lower tumor expression in KIRC, KIRP, HNSC and READ and higher tumor expression in THCA and LUAD. The KIRC box plot shows higher MUC20 RNA expression in normal versus tumor tissue (log2 FC = −3.088, t-test p < 0.001).
This table shows molecular features associated with MUC20 in patient tissues and cancer cell lines. In patient samples, MUC20 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and PANCREAS.
